Equities.com It's a broad-spectrum antibiotic in the macrolide family. The significance is that solithromycin doesn't just attack bacteria, it prevents them from replicating within cell membranes. The antibiotic is in Phase 3 for community-acquired bacterial ...
Pharmacy Times In a notable departure from previous guidelines, this new guideline recommends use of long-term macrolide antibiotic therapy to reduce the risk of COPD exacerbations in patients with moderate to severe COPD who have had 1 or more exacerbations in the ... and more »
AAP News (subscription) Infants treated with macrolide antibiotics were at a significantly increased risk of developing infantile hypertrophic pyloric stenosis (IHPS), according to a study of 999,378 babies born in Denmark between 1996-2011. Macrolides, including erythromycin ...
Triangle Business Journal Patients could receive intravenous, oral suspension or oral capsule formulations of Cempra's investigational drug solithromycin, a fourth gener...
Cystic Fibrosis News Today This therapeutic is a fourth generation macrolide and an investigational antibiotic. The Biomedical Advanced Research and Development Authority (BARDA) will provide funding to the two clinical assessments of solithromycin. Recently, Cempra completed a ...
Medscape Macrolide treatment of Mycoplasma pneumoniae may or may not benefit children with community-acquired lower respiratory tract infection (CA-LRTI), according to an article published in the June issue of Pediatrics. Eric Biondi, MD, from the Department of ...
HCPLive Community-acquired pneumonia presents a number of dilemmas. Patients may be elderly or frail and it's sometimes difficult to identify the infectious organism initially. There is considerable debate about the selection of an appropriate antibiotic or ...
Seeking Alpha The Drug is a ketolide antibiotic, which is in the macrolide class of antibiotics. In our opinion, results are likely to be positive because of solid Phase II data versus its comparator levoflaxacin. The FDA also is being more lenient with efficacy ... and more »
